SBSB
TEVA icon

Sullivan, Bruyette, Speros & Blaney’s Teva Pharmaceuticals TEVA Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$389K Hold
33,750
– – 0.02% 210
2020
Q4 		$326K Hold
33,750
– – 0.02% 213
2020
Q3 		$304K Buy
+33,750
New +$357K 0.02% 199

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's TEVA Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney held its Teva Pharmaceuticals (TEVA) position steady in Q1 2021 at 33,750 shares worth $389K. The position accounts for 0.02% of the portfolio, ranked #210.

Sullivan, Bruyette, Speros & Blaney first reported a position in TEVA in Q3 2020 and has held it in 3 quarters since. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • Sullivan, Bruyette, Speros & Blaney held 33,750 shares of Teva Pharmaceuticals worth $389K as of Q1 2021.
  • Sullivan, Bruyette, Speros & Blaney left its Teva Pharmaceuticals share count unchanged in Q1 2021.
  • Teva Pharmaceuticals made up 0.02% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #210 holding.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Teva Pharmaceuticals in Q3 2020 and has held it in 3 quarters since.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.